Donanemab is an investigational antibody therapy designed to slow cognitive decline in early-stage Alzheimer’s disease. It targets and removes amyloid plaques in the brain, a hallmark of the condition. Administered via monthly intravenous infusions, it benefits patients with mild symptoms and confirmed amyloid pathology, offering a potential disease-modifying approach.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends